 CAMBRIDGE, Mass., Nov. 02, 2020 GLOBE NEWSWIRE -- Trillium Therapeutics Inc. Trillium or the Company NASDAQTSX: TRIL, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the formation of a Scientific Advisory Board SAB, including Karen Ferrante, MD, Gordon Freeman, PhD, Tom Reynolds, MD, PhD, Steven Rosen, MD, and Jeff Settleman, PhD. 